Onconova Therapeutics, Inc. (NASDAQ:ONTX – Get Rating) – Research analysts at HC Wainwright dropped their FY2022 earnings per share estimates for Onconova Therapeutics in a report issued on Tuesday, November 15th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($0.92) for the year, down from their prior estimate of ($0.82). The consensus estimate for Onconova Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Onconova Therapeutics’ Q4 2022 earnings at ($0.27) EPS and FY2023 earnings at ($0.85) EPS.
Separately, StockNews.com began coverage on shares of Onconova Therapeutics in a research report on Thursday, November 10th. They set a “hold” rating for the company.
Onconova Therapeutics Stock Performance
Institutional Investors Weigh In On Onconova Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Onconova Therapeutics by 21.7% during the third quarter. Vanguard Group Inc. now owns 622,958 shares of the biopharmaceutical company’s stock worth $549,000 after acquiring an additional 110,965 shares during the last quarter. Renaissance Technologies LLC lifted its position in Onconova Therapeutics by 3.6% during the second quarter. Renaissance Technologies LLC now owns 333,323 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 11,580 shares during the last quarter. Millennium Management LLC raised its position in shares of Onconova Therapeutics by 154.6% in the second quarter. Millennium Management LLC now owns 61,390 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 37,275 shares in the last quarter. Finally, Beacon Pointe Advisors LLC raised its position in shares of Onconova Therapeutics by 147.0% in the first quarter. Beacon Pointe Advisors LLC now owns 46,027 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 27,396 shares in the last quarter. 8.83% of the stock is currently owned by institutional investors and hedge funds.
About Onconova Therapeutics
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Onconova Therapeutics (ONTX)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.